Besides breast cancer, CDK4/6 inhibitors have been shown as a promising therapy for several other cancers, including glioma [47], multiple myeloma [48], and liposarcoma [49], and are currently being evaluated for a variety of other cancers [20,50]. Here, CDK4 is linked to breast cancer.